Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.36 |
| ▸ | NPC1 | O15118 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310990 | 1.00 | RAB9A (0.36) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL19555597 | 0.80 | RAB9A (0.40) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1939500 | 0.77 | RAB9A (0.36) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22138861 | 0.76 | MIF (0.39) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL24414259 | 0.73 | MIF (0.47) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6649744 | 0.72 | MAPT (0.38) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7985945 | 0.72 | MAPT (0.35) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7985951 | 0.72 | MAPT (0.35) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2481016 | 0.71 | GABRG2 (0.42) | ALDH1A1LMNA | |
| SCHEMBL22398513 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042800-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | BASILEA PHARMACEUTICA INT AG ALLSCHWIL (CH) | 2026-02-12 | — | — | US | disclosed |
| US-20250171398-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20240336654-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Universität Zürich (CH) | 2024-10-10 | — | — | US | disclosed |
| US-20240228555-A9 | ANTIMICROBIAL PEPTIDOMIMETICS | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2024-07-11 | — | — | US | disclosed |
| EP-4380689-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Basilea Pharmaceutica International AG, Allschwil (CH) | 2024-06-12 | — | — | EP | disclosed |
| US-20240132553-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | SPEXIS AG (CH) | 2024-04-25 | — | — | US | disclosed |
| US-20230295234-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | SPEXIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| EP-3653230-B1 | COMPOSITIONS, METHODS AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING INC (US) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023012319-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | SPEXIS AG (CH) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023287736-A1 | NOVEL BIS-AMIDE CONTAINING COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2000056729-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | disclosed |
| EP-1036063-A1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-09-20 | — | — | EP | disclosed |
| EP-0984778-A4 | NEUROPEPTIDE-Y LIGANDS | ALANEX CORP (US) | 2000-06-07 | — | — | EP | disclosed |
| EP-0984778-A1 | NEUROPEPTIDE-Y LIGANDS | Alanex Corporation (US) | 2000-03-15 | — | — | EP | disclosed |
| US-6037356-A | ANTICOAGULANTS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| WO-1999037667-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999026926-A1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| US-5739163-A | ANTICOAGULANTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| WO-1998007420-A1 | NEUROPEPTIDE-Y LIGANDS | AGOURON ACQUISITION CORP. (US) | 1998-02-26 | — | — | WO | disclosed |
| US-5523302-A | ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171398-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | RAB9A 1536/4885NPC1 532/4885SMN1; SMN2 453/4885 |
| US-20260042800-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | CUTA, NGLY1, P4HB | RAB9A 3139/4885NPC1 2457/4885SMN1; SMN2 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.